Nature Communications,
Год журнала:
2022,
Номер
13(1)
Опубликована: Май 13, 2022
Abstract
Mass-spectrometry-based
proteomic
data
on
human
tumors—combined
with
corresponding
multi-omics
data—present
opportunities
for
systematic
and
pan-cancer
proteogenomic
analyses.
Here,
we
assemble
a
compendium
dataset
of
proteomics
2002
primary
tumors
from
14
cancer
types
17
studies.
Protein
expression
genes
broadly
correlates
mRNA
levels
or
copy
number
alterations
(CNAs)
across
tumors,
but
notable
exceptions.
Based
unsupervised
clustering,
separate
into
11
distinct
proteome-based
subtypes
spanning
multiple
tissue-based
types.
Two
are
enriched
brain
one
subtype
associating
MYC,
Wnt,
Hippo
pathways
high
CNA
burden,
another
metabolic
low
burden.
Somatic
alteration
in
pathway
associates
higher
activity
as
inferred
by
proteome
transcriptome
data.
A
substantial
fraction
cancers
shows
MYC
without
gain
mutations
noncanonical
roles
MYC.
Our
proteogenomics
survey
reveals
the
interplay
between
genome
tumor
lineages.
HepatoBiliary Surgery and Nutrition,
Год журнала:
2020,
Номер
9(4), С. 452 - 463
Опубликована: Авг. 1, 2020
Importance:
Approximately
half
of
newly-diagnosed
hepatocellular
carcinoma
(HCC)
cases
in
the
world
occur
China,
with
hepatitis
B
virus
(HBV)
infection
being
predominant
risk
factor.
Recently,
guidelines
for
management
Chinese
HCC
patients
were
updated.
Objective:
The
past
decade
has
witnessed
a
great
improvement
(HCC).
This
study
reviews
recommendations
2019
and
makes
comparison
practices
from
Western
world.
Evidence
Review:
updated
on
surveillance,
diagnosis,
treatment
algorithm
summarized,
comparisons
among
guidelines,
European
Association
Study
Liver
(EASL)
American
Diseases
(AASLD)
made.
Findings:
Besides
imaging
pathological
diagnoses,
novel
biomarkers
like
seven-micro-RNA
panel
are
advocated
early
diagnoses
therapeutic
efficacy
evaluation
guidelines.
China
liver
cancer
(CNLC)
staging
system,
proposed
2017
continues
to
be
standard
model
patient
classification,
subsequent
modifications
updates
made
allocations.
Compared
Barcelona
Clinic
Cancer
(BCLC)
CNLC
system
employs
resection,
transplantation,
transarterial
chemoembolization
(TACE)
more
progressed
HCC.
TACE
combination
other
regional
therapies
ablation
or
systemic
sorafenib
also
encouraged
select
China.
treatments
have
evolved
considerably
since
lenvatinib,
regorafenib,
carbozantinib,
ramucirumab
immune
checkpoint
inhibitors
(ICIs)were
first
prescribed
as
first-line
second-line
agents.
Conclusions
Relevances:
Novel
biomarkers,
operative
techniques
recommended
guideline.
More
aggressive
modalities
suggested
HBV-related
Signal Transduction and Targeted Therapy,
Год журнала:
2021,
Номер
6(1)
Опубликована: Фев. 23, 2021
Abstract
N6-methyladenosine
(m6A),
and
its
reader
protein
YTHDF1,
play
a
pivotal
role
in
human
tumorigenesis
by
affecting
nearly
every
stage
of
RNA
metabolism.
Autophagy
activation
is
one
the
ways
which
cancer
cells
survive
hypoxia.
However,
possible
involvement
m6A
modification
mRNA
hypoxia-induced
autophagy
was
unexplored
hepatocellular
carcinoma
(HCC).
In
this
study,
specific
variations
YTHDF1
expression
were
detected
YTHDF1-overexpressing,
-knockout,
-knockdown
HCC
cells,
organoids,
patient-derived
xenograft
(PDX)
murine
models.
significantly
correlated
vitro;
significant
overexpression
tissues
associated
with
poor
prognosis.
Multivariate
cox
regression
analysis
identified
as
an
independent
prognostic
factor
patients
HCC.
Multiple
models
confirmed
that
deficiency
inhibited
autophagy,
growth,
metastasis.
Luciferase
reporter
assays
chromatin
immunoprecipitation
demonstrated
HIF-1α
regulated
transcription
directly
binding
to
promoter
region
under
The
results
methylated
sequencing,
proteomics,
polysome
profiling
indicated
contributed
translation
autophagy-related
genes
ATG2A
ATG14
m6A-modified
mRNA,
thus
facilitating
malignancy
Taken
together,
HIF-1α-induced
progression
via
promoting
m6A-dependent
manner.
Our
findings
suggest
potential
biomarker
therapeutic
target
for
Cell,
Год журнала:
2020,
Номер
182(1), С. 226 - 244.e17
Опубликована: Июль 1, 2020
Lung
cancer
in
East
Asia
is
characterized
by
a
high
percentage
of
never-smokers,
early
onset
and
predominant
EGFR
mutations.
To
illuminate
the
molecular
phenotype
this
demographically
distinct
disease,
we
performed
deep
comprehensive
proteogenomic
study
on
prospectively
collected
cohort
Taiwan,
representing
stage,
predominantly
female,
non-smoking
lung
adenocarcinoma.
Integrated
genomic,
proteomic,
phosphoproteomic
analysis
delineated
attributes
hallmarks
tumor
progression.
Mutational
signature
revealed
age-
gender-related
mutagenesis
mechanisms,
prevalence
APOBEC
mutational
younger
females
over-representation
environmental
carcinogen-like
signatures
older
females.
A
proteomics-informed
classification
distinguished
clinical
characteristics
stage
patients
with
Furthermore,
integrated
protein
network
cellular
remodeling
underpinning
trajectories
nominated
candidate
biomarkers
for
patient
stratification
therapeutic
intervention.
This
multi-omic
architecture
may
help
develop
strategies
management
never-smoker
Biomedicine & Pharmacotherapy,
Год журнала:
2020,
Номер
132, С. 110851 - 110851
Опубликована: Окт. 17, 2020
The
WNT/β-catenin
signaling
pathway
is
a
highly
conserved
and
tightly
controlled
molecular
mechanism
that
regulates
embryonic
development,
cellular
proliferation
differentiation.
Of
note,
accumulating
evidence
has
shown
the
aberrant
of
promotes
development
and/or
progression
liver
cancer,
including
hepatocellular
carcinoma
(HCC)
cholangiocarcinoma
(CCA),
two
most
prevalent
primary
tumours
in
adults.
There
are
different
WNT
pathways
have
been
identified,
which
were
termed
non-canonical
canonical
pathways,
latter
involving
activation
β-catenin.
β-catenin,
acting
as
an
intracellular
signal
transducer
pathway,
encoded
by
CTNNB1
plays
critical
role
tumorigenesis.
In
past
research,
tumors
mutations
genes
encoding
key
components
pathway.
addition,
several
other
also
can
crosswalk
with
this
review,
we
discuss
relevant
mechanisms
action
regulation
pathophysiology
cancers,
well
therapeutics.
Clinical Proteomics,
Год журнала:
2020,
Номер
17(1)
Опубликована: Май 24, 2020
Abstract
Cancer
biomarkers
have
transformed
current
practices
in
the
oncology
clinic.
Continued
discovery
and
validation
are
crucial
for
improving
early
diagnosis,
risk
stratification,
monitoring
patient
response
to
treatment.
Profiling
of
tumour
genome
transcriptome
now
established
tools
novel
biomarkers,
but
alterations
proteome
expression
more
likely
reflect
changes
pathophysiology.
In
past,
clinical
diagnostics
strongly
relied
on
antibody-based
detection
strategies,
these
methods
carry
certain
limitations.
Mass
spectrometry
(MS)
is
a
powerful
method
that
enables
increasingly
comprehensive
insights
into
advance
personalized
medicine.
this
review,
recent
improvements
MS-based
proteomics
highlighted
with
focus
oncology.
We
will
provide
detailed
overview
clinically
relevant
samples
types,
as
well
as,
consideration
sample
preparation
methods,
protein
quantitation
MS
configurations,
data
analysis
pipelines
currently
available
researchers.
Critical
each
step
necessary
address
pressing
questions
cancer
diagnosis
prognosis.
While
majority
studies
clinically-relevant
there
growing
demand
rigorous
biomarker
validation.
These
high-throughput
targeted
assays
multi-centre
standardized
protocols.
Additionally,
sensitivity
opening
door
new
classes
tumour-specific
proteoforms
including
post-translational
modifications
variants
originating
from
genomic
aberrations.
Overlaying
proteomic
complement
transcriptomic
datasets
forges
field
proteogenomics,
which
shows
great
potential
improve
our
understanding
biology.
Overall,
advancements
not
only
solidify
proteomics’
integral
position
research,
also
accelerate
shift
towards
becoming
regular
component
routine
practice.
Liver International,
Год журнала:
2022,
Номер
42(9), С. 2029 - 2041
Опубликована: Март 23, 2022
Liver
cancer
is
the
fifth
most
common
and
second
leading
cause
of
malignant
death
in
Asia,
Asia
reports
72.5%
world's
cases
2020.
As
histological
type,
hepatocellular
carcinoma
(HCC)
accounts
for
majority
incidence
mortality
liver
cases.
This
review
presents
changing
epidemiology
HCC
Asian
countries
recent
years.
Globally,
aged,
male
populations
remain
group
with
highest
risk
HCC.
Hepatitis
B
virus
(HBV)
hepatitis
C
(HCV)
are
still
factors
a
slight
decline
countries,
which
mainly
attributed
to
HBV
vaccination
newborns,
prevention
HCV
horizontal
transmission
treatment
chronic
hepatitis.
However,
prevalence
caused
by
metabolic
factors,
including
syndrome,
obesity
non-alcoholic
fatty
diseases,
increasing
rapidly
may
eventually
become
major
Excessive
alcohol
consumption
continues
be
an
important
factor
as
average
growing.
Hopefully,
great
effort
has
been
made
better
regions,
significantly
prolongs
survival
patients.
tend
use
more
aggressive
intervention
than
European
American
but
it
remains
unclear
whether
this
preference
related
prognosis.
In
conclusion,
disease
burden
management
should
adjusted
dynamically
based
on
epidemiology.
